Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models

BACKGROUND: Auranofin, a Food and Drug Administration–approved anti-rheumatic agent with anticancer properties for lung and ovarian cancer, has never been studied for pancreatic cancer. We hypothesize that auranofin may prevent pancreatic ductal adenocarcinoma progression by inhibition of Txnrd1 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Rios Perez, Mayrim V., Roife, David, Dai, Bingbing, Pratt, Michael, Dobrowolski, Ryszard, Kang, Ya'an, Li, Xinqun, Augustine, Jithesh J., Zielinski, Rafal, Priebe, Waldemar, Fleming, Jason B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083010/
https://www.ncbi.nlm.nih.gov/pubmed/33981979
http://dx.doi.org/10.1016/j.sopen.2019.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083010/
https://www.ncbi.nlm.nih.gov/pubmed/33981979
http://dx.doi.org/10.1016/j.sopen.2019.05.004

Ejemplares similares